Patents by Inventor Wilma Thuer

Wilma Thuer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10316316
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: June 11, 2019
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: David L Lewis, David B Rozema, Darren H Wakefield, Torsten Hoffman, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Publication number: 20170204408
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Application
    Filed: April 19, 2016
    Publication date: July 20, 2017
    Inventors: David L Lewis, David B Rozema, Darren H Wakefield, Torsten Hoffman, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Publication number: 20160222384
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Application
    Filed: April 19, 2016
    Publication date: August 4, 2016
    Inventors: David L Lewis, David B Rozema, Darren H Wakefield, I, Torsten Hoffman, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Patent number: 9011919
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 21, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Eric Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Patent number: 8853132
    Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: October 7, 2014
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
  • Publication number: 20140045719
    Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.
    Type: Application
    Filed: September 13, 2013
    Publication date: February 13, 2014
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
  • Patent number: 8569515
    Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: October 29, 2013
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
  • Publication number: 20130245091
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Application
    Filed: September 14, 2012
    Publication date: September 19, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Eric A. Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Publication number: 20110212861
    Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.
    Type: Application
    Filed: May 3, 2011
    Publication date: September 1, 2011
    Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
  • Publication number: 20110207799
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 25, 2011
    Applicant: ROCHE MADISON INC.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis